Kauvery Hospital, Alwarpet, has successfully treated two failing heart valves in a patient without repeat open-heart surgery, ...

Kauvery Hospital, Alwarpet, has successfully treated two failing heart valves in a patient without repeat open-heart surgery, ...

SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

Data on valve durability with transcatheter aortic valve replacement are reassuring at 7 years, with implications for ...

Edwards Lifesciences gains attention after fresh valve data as structural heart devices, valuation debate, and healthcare ...

In mostly women with small aortic annuli, self-expanding valves maintained superior hemodynamics and far lower valve ...

Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's ...

“TAVR with the Sapien 3 platform demonstrated comparable 7-year durability to surgery, supporting its use as a treatment option in lifetime management of low-risk patients with symptomatic severe AS,” ...

On Monday, the Centers for Medicare & Medicaid Services (CMS) proposed removing the coverage with evidence development (CED) requirement for Transcatheter Aortic Valve Replacement (TAVR) in patients ...

The proposed Medicare coverage change could help Edwards Lifesciences gain market share from Medtronic and Boston Scientific, an analyst said.

DJ Carvolix presents promising clinical data on the TAVIPILOT platform at New York Valves 2026 Affluent Medical Carvolix presents promising clinical data on the TAVIPILOT platform at New York Valves ...

The Minnesota Timberwolves' season came to an end on Friday night at the hands of the San Antonio Spurs in the form of a 30-point beatdown in front of a capacity home crowd at Target Center. For the ...